NewAmsterdam Pharma Co N.V.
NAMS Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$20.50
KIRA · Stoqly’s AI analyst, in plain words
- NewAmsterdam Pharma Co N.V. had $22.5M of revenue in fiscal 2025, down 50.6% on the year before.
- Its operating margin was −1,002.9%, down 616.0 pts: of every 100 in sales, about −1,003 is left after running the business.
- NewAmsterdam Pharma Co N.V. lost $204M in fiscal 2025.
- Free cash flow was −$148M in fiscal 2025, −657.8% of revenue.
Market cap
$2.5B
P/E
—
Revenue
$22.5M
Net income
−$204M
Free cash flow
−$148M
Operating margin
−1,002.9%
NewAmsterdam Pharma Co N.V. in 30 seconds · fiscal 2025
Are sales growing?
−50.6%
No. Sales fell 50.6% last year.
Does it make a profit?
−905.7%
No. It lost money last year.
Does profit turn into cash?
−657.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What NewAmsterdam Pharma Co N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 18, 2026
- Legal name
- NewAmsterdam Pharma Co N.V.
- CIK
- 0001936258
NewAmsterdam Pharma Co N.V. · NAMS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $103M | $14.1M | $45.6M | $22.5M |
| Revenue growth | — | — | −86.3% | 223.4% | −50.6% |
| Operating margin | — | −3.5% | −1,298.6% | −386.9% | −1,002.9% |
| Net income | −$41.8M | −$22.6M | −$177M | −$242M | −$204M |
| Net margin | — | −22.0% | −1,255.8% | −530.3% | −905.7% |
| Diluted EPS | −$3.81 | −$1.19 | −$2.15 | −$2.56 | −$1.72 |
| Cash | |||||
| Cash from operations | −$29.5M | $10.7M | −$141M | −$159M | −$148M |
| Capital expenditure | $0.0M | $0.2M | $0.0M | $0.7M | $0.2M |
| Free cash flow | −$29.5M | $10.4M | −$141M | −$159M | −$148M |
| FCF margin | — | 10.2% | −1,002.4% | −349.5% | −657.8% |
| Share count change | — | 72.8% | 333.2% | 14.8% | 25.5% |
| Debt and strength | |||||
| Cash and short-term investments | — | $468M | $340M | $834M | $636M |
| Shareholders' equity | −$114M | $430M | $288M | $758M | $683M |
| Current ratio | — | 13.3x | 7.0x | 8.1x | 7.9x |
| Interest coverage | −85.1x | −12.4x | — | — | — |
| Returns and quality | |||||
| Return on equity | — | −14.3% | −49.3% | −46.2% | −28.3% |
| Return on tangible equity | — | −5.3% | −61.4% | −31.9% | −29.8% |
| Piotroski F-score | — | — | 1 | 4 | 2 |
| Altman Z'' | — | 14.4 | 4.3 | 9.7 | 8.2 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$63.3M
6 insiders
Of sales under plans
71%
$44.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NewAmsterdam Pharma Co N.V. · NAMS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $20.50 a share, the company is worth $2.5B.
Source: SEC EDGAR XBRL filings (CIK 0001936258). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.